#Israel #Haifa #aMoon #Gastroenterology #MAGENTIQ EYE

MAGENTIQ EYE's Milestone in Gastroenterology

In a significant advancement for healthcare technology, MAGENTIQ EYE LTD., an innovative leader in AI-supported decision-making software for gastroenterology, successfully concluded its Series A funding round. This strategic round, primarily led by aMoon, marks a pivotal point in the company's journey towards enhancing gastroenterological practices through cutting-edge AI technology.

The Role of aMoon and Funding Partners

aMoon, Israel's largest venture capital fund focused on HealthTech, spearheaded the funding effort. A range of investors joined aMoon, including Norgine Ventures (Netherlands), Nina Capital (EU and USA), Namarel Ventures (Spain), and Nova Capital (Italy), along with private investors Sake Bosch and Roon Doornink from the USA. The collaboration with aMoon will also bring Roy Wiesner onto MAGENTIQ EYE's board of directors, providing strategic counsel driven by extensive experience in successful health technology enterprises.

Impact of MAGENTIQ-COLO™ the AI Solution

MAGENTIQ EYE's flagship product, MAGENTIQ-COLO™, cleared by both FDA and CE, revolutionizes the detection and analysis of polyps during colonoscopies. This powerful tool not only boosts adenoma detection rates but also provides real-time insights, estimating polyp size and type, as well as delivering advanced, AI-generated reports. Such capabilities are crucial as the demand for effective gastroenterological diagnostics intensifies worldwide.

“Achieving this investment milestone represents a significant achievement for MAGENTIQ EYE. We are thrilled to integrate aMoon and Roy Wiesner into our vision,” stated Dr. Dror Zur, the founder and CEO of MAGENTIQ EYE. “With aMoon's backing, we will accelerate our innovation and market access to meet growing demands, as seen through our robust pipeline of trial and purchase requests in the US and Europe. Our advanced diagnostic tools are set to reach an increasing number of healthcare professionals and patients globally.”

Future Developments: Clinical Trials and Expansion

The funding from this Series A round will not only enhance MAGENTIQ EYE's capabilities but also support the growth of their commercial operations in key markets like the United States and Europe. The company is currently conducting clinical trials focused on developing diagnostic tools aimed at specialized gastrointestinal diseases, including ulcerative colitis and early-stage Barrett’s esophagus dysplasia, as well as gastric intestinal metaplasia. Additionally, MAGENTIQ EYE is working towards automating quality indicators for gastrointestinal procedures, enhancing the overall patient care experience.

aMoon's Commitment to Health Technology Innovation

aMoon's involvement underscores its commitment to fostering technology-driven solutions that enhance patient care across the globe. “We are proud to partner with MAGENTIQ EYE, a leader in AI-driven colonoscopy. Their solution is recognized as the most accurate on the market, equipped with a wide range of functions, scalability, and flexibility for both gastrointestinal and laparoscopic applications,” remarked Wiesner. The investment reflects aMoon's mission to support health technology solutions that revolutionize patient care, evident in MAGENTIQ's promising initial commercial trajectory and the increased interest from strategic industry players.

About MAGENTIQ EYE

Founded in 2014, MAGENTIQ EYE is establishing new benchmarks in colonoscopy with its AI-assisted solutions—proving to be some of the most effective available today. With global recognition from the gastroenterology community and numerous procedures supported by MAGENTIQ-COLO™, the company is making strides toward saving lives. For more information, visit www.magentiq.com.

About aMoon

aMoon is a global venture capital fund centered on health technology and life sciences, based in Israel with $1.3 billion in assets under management. It partners with entrepreneurs who leverage innovative science and technology to transform healthcare, enhancing the quality of life for individuals. Supported by a team of scientists and industry leaders, aMoon connects its portfolio companies with global technology and investment hubs, facilitating growth and innovation in health technology. They provide early-stage investment through their Velocity Fund and support later-stage companies through their Growth Fund.

For media inquiries, please contact:
Kim Mohr
Amendola Communications on behalf of MAGENTIQ EYE
Email: [email protected]